甲磺酸伊马替尼治疗慢性粒细胞白血病的效果观察
|
摘要
目的:观察甲磺酸伊马替尼治疗慢性粒细胞白血病的临床效果。方法:选取50例慢性粒细胞白血病患者为研究对象,根据入院顺序将其分为观察组和对照组各25例。对照组采用常规药物联合化疗,观察组采用甲磺酸伊马替尼联合常规药物和化疗。比较两组临床治疗效果、外周血白细胞计数、血红蛋白含量、不良反应发生率。结果:两组外周血白细胞计数、血红蛋白含量均明显改善,且观察组改善程度明显大于对照组,差异有统计学意义(P<0.05);观察组临床治疗总有效率为88.00%(22/25),明显高于对照组的60.00%(15/25),差异有统计学意义(P<0.05);观察组不良反应发生率是24.00%(6/25),明显低于对照组的52.00%(13/25),差异有统计学意义(P<0.05)。结论:甲磺酸伊马替尼有利于降低慢性粒细胞白血病患者的外周血白细胞计数,提高其血红蛋白含量,治疗效果优于常规药物联合化疗,且安全性高。
Objective: To explore clinical effects of Imatinib mesylate in treatment of chronic myeloid leukemia. Methods: 50 patients with chronic myeloid leukemia were selected as the research objects, and divided into observation group(n=25) and control group(n=25) according to the order of admission. The observation group was treated with Imatinib mesylate combined with conventional drugs and chemotherapy, while the control group was treated with conventional drugs combined with chemotherapy. The clinical efficacy, peripheral white blood cell count, hemoglobin content and incidence of adverse reactions were compared between the two groups. Results: The peripheral white blood cell count and hemoglobin content of the two groups were significantly improved, the improvement degree of the observation group was significantly higher than that of the control group, and the difference was statistically significant(P<0.05). The total effective rate of the clinical treatment in the observation group was 88.00%(22/25), which was obviously higher than 60.00%(15/25) of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 24.00%(6/25), which was significantly lower than 52.00%(13/25)of the control group, and the difference was statistically significant(P<0.05). Conclusions: Imatinib mesylate in the treatment of the patients with chronic myeloid leukemia is beneficial to reduce the peripheral white blood cell count and improve the hemoglobin content. Moreover, it is superior to the conventional drugs combined with chemotherapy with high safety.
Objective: To explore clinical effects of Imatinib mesylate in treatment of chronic myeloid leukemia. Methods: 50 patients with chronic myeloid leukemia were selected as the research objects, and divided into observation group(n=25) and control group(n=25) according to the order of admission. The observation group was treated with Imatinib mesylate combined with conventional drugs and chemotherapy, while the control group was treated with conventional drugs combined with chemotherapy. The clinical efficacy, peripheral white blood cell count, hemoglobin content and incidence of adverse reactions were compared between the two groups. Results: The peripheral white blood cell count and hemoglobin content of the two groups were significantly improved, the improvement degree of the observation group was significantly higher than that of the control group, and the difference was statistically significant(P<0.05). The total effective rate of the clinical treatment in the observation group was 88.00%(22/25), which was obviously higher than 60.00%(15/25) of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 24.00%(6/25), which was significantly lower than 52.00%(13/25)of the control group, and the difference was statistically significant(P<0.05). Conclusions: Imatinib mesylate in the treatment of the patients with chronic myeloid leukemia is beneficial to reduce the peripheral white blood cell count and improve the hemoglobin content. Moreover, it is superior to the conventional drugs combined with chemotherapy with high safety.
引文
[1]祝文娟,尹大伟,李琚,等.国产甲磺酸伊马替尼片治疗慢性粒细胞白血病的临床观察[J].中国药房,2016,27(5):671-673.
[2]中国抗癌协会血液肿瘤专业委员会.中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J].中华血液学杂志,2016,37(10):837-845.
[3]佟丹江.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期的疗效观察[J].中国现代药物应用,2016,10(9):141-142.
[4]黄琴,刘虹,李燕,等.国产甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期患者早期效果[J].肿瘤研究与临床,2016,28(12):811-814.
[5]刘文玲,冀林华,李占全,等.达沙替尼与伊马替尼治疗慢性粒细胞白血病慢性期患者效果的Meta分析[J].白血病·淋巴瘤,2016,25(4):228-233.
[6]王志永,曲伟,邹慧琳,等.减低剂量甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期患者一例并文献复习[J].白血病·淋巴瘤,2017,26(11):689-692.
[7]王良妥,张湘兰,司徒健瑜,等.甲磺酸伊马替尼对慢性髓系白血病患者效果的相关因素研究[J].安徽医药,2016,20(1):171-174.
[8]曾慧敏,张乐萍.儿童慢性粒细胞白血病临床特点及治疗进展[J].中华临床医师杂志(电子版),2016,10(11):1617-1621.
[9]赖文鸿,李海亮,廖长风,等.甲磺酸伊马替尼联合大剂量阿糖胞苷治疗复发Ph染色体阳性急性淋巴细胞白血病的疗效观察[J].中国医院用药评价与分析,2016,16(12):1605-1607.
[10]丁卓玲,邓明凤.初发慢性粒细胞白血病采用甲磺酸伊马替尼治疗临床检验观察[J].湖北中医药大学学报,2016,18(4):109-112.
[11]张雪飞.国产甲磺酸伊马替尼片治疗慢性粒细胞白血病的疗效及安全性分析[J].当代医学,2017,23(16):43-45.
[2]中国抗癌协会血液肿瘤专业委员会.中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J].中华血液学杂志,2016,37(10):837-845.
[3]佟丹江.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期的疗效观察[J].中国现代药物应用,2016,10(9):141-142.
[4]黄琴,刘虹,李燕,等.国产甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期患者早期效果[J].肿瘤研究与临床,2016,28(12):811-814.
[5]刘文玲,冀林华,李占全,等.达沙替尼与伊马替尼治疗慢性粒细胞白血病慢性期患者效果的Meta分析[J].白血病·淋巴瘤,2016,25(4):228-233.
[6]王志永,曲伟,邹慧琳,等.减低剂量甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期患者一例并文献复习[J].白血病·淋巴瘤,2017,26(11):689-692.
[7]王良妥,张湘兰,司徒健瑜,等.甲磺酸伊马替尼对慢性髓系白血病患者效果的相关因素研究[J].安徽医药,2016,20(1):171-174.
[8]曾慧敏,张乐萍.儿童慢性粒细胞白血病临床特点及治疗进展[J].中华临床医师杂志(电子版),2016,10(11):1617-1621.
[9]赖文鸿,李海亮,廖长风,等.甲磺酸伊马替尼联合大剂量阿糖胞苷治疗复发Ph染色体阳性急性淋巴细胞白血病的疗效观察[J].中国医院用药评价与分析,2016,16(12):1605-1607.
[10]丁卓玲,邓明凤.初发慢性粒细胞白血病采用甲磺酸伊马替尼治疗临床检验观察[J].湖北中医药大学学报,2016,18(4):109-112.
[11]张雪飞.国产甲磺酸伊马替尼片治疗慢性粒细胞白血病的疗效及安全性分析[J].当代医学,2017,23(16):43-45.